title: Effects of inhaled high-molecular weight hyaluronan in inflammatory airway disease.
abstract: Cystic fibrosis (CF) is a chronic inflammatory disease that is affecting thousands of patients worldwide. Adjuvant anti-inflammatory treatment is an important component of cystic fibrosis treatment, and has shown promise in preserving lung function and prolonging life expectancy. Inhaled high molecular weight hyaluronan (HMW-HA) is reported to improve tolerability of hypertonic saline and thus increase compliance, and has been approved in some European countries for use as an adjunct to hypertonic saline treatment in cystic fibrosis. However, there are theoretical concerns that HMW-HA breakdown products may be pro-inflammatory. In this clinical pilot study we show that sputum cytokines in CF patients receiving HMW-HA are not increased, and therefore HMW-HA does not appear to adversely affect inflammatory status in CF airways.
authors.affiliation: Hospital Universitario Ramón y Cajal, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spain.
authors.forename: Adelaida
authors.initials: A
authors.lastname: Lamas
authors.affiliation: Division of Intramural Research, National Institute of Environmental Health Sciences, Research Triangle Park, Durham, NC, USA.
authors.forename: Jamie
authors.initials: J
authors.lastname: Marshburn
authors.affiliation: Division of Intramural Research, National Institute of Environmental Health Sciences, Research Triangle Park, Durham, NC, USA.
authors.forename: Vandy P
authors.initials: VP
authors.lastname: Stober
authors.affiliation: University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
authors.forename: Scott H
authors.initials: SH
authors.lastname: Donaldson
authors.affiliation: Division of Intramural Research, National Institute of Environmental Health Sciences, Research Triangle Park, Durham, NC, USA. garantziotis@niehs.nih.gov.|National Institute of Environmental Health Sciences, 111 TW Alexander Dr, Research Triangle Park, Durham, NC, 27709, USA. garantziotis@niehs.nih.gov.
authors.forename: Stavros
authors.identifier: 0000-0003-4007-375X
authors.initials: S
authors.lastname: Garantziotis
mesh_terms: D000280:Administration, Inhalation; D000293:Adolescent; D002648:Child; D003550:Cystic Fibrosis / Q000175:diagnosis / Q000188:drug therapy* / Q000276:immunology; D016207:Cytokines / Q000276:immunology; D005260:Female; D006801:Humans; D006820:Hyaluronic Acid / Q000008:administration & dosage* / Q000009:adverse effects / Q000737:chemistry; D008297:Male; D008970:Molecular Weight; D010865:Pilot Projects; D011014:Pneumonia / Q000175:diagnosis / Q000188:drug therapy* / Q000276:immunology; D012462:Saline Solution, Hypertonic / Q000008:administration & dosage* / Q000009:adverse effects; D013183:Sputum / Q000276:immunology; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D016207:Cytokines; D012462:Saline Solution, Hypertonic; D006820:Hyaluronic Acid
keywords: Airway inflammation; Cystic fibrosis; Hyaluronan; Induced sputum